First, while targeting c-FOS therapy can reduce neutrophil infiltration and NETs formation in breast cancer, we did not investigate changes and interactions of other immune cells, such as T cells, within the immune environment, which requires further research in the future. This evidence concerns the gene FOS and breast carcinoma.